Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
Harrow (Nasdaq: HROW) will present at Leerink Partner’s 2026 Global Healthcare Conference on Tuesday, March 10, 2026 at 8:40 AM ET in Miami, Florida.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Harrow (Nasdaq: HROW) will present at Leerink Partner’s 2026 Global Healthcare Conference on Tuesday, March 10, 2026 at 8:40 AM ET in Miami, Florida. The management presentation will be webcast live on the company website, with a replay available for approximately 90 days after the event.
Details
News Market Reaction – HROW
On Mar 4, the day this news came out, HROW closed 1.59% above the previous close.
Data tracked by StockTitan Argus for the Mar 4 session.
Key Figures
- Conference date
- March 10, 2026
- Leerink Partner’s 2026 Global Healthcare Conference presentation date
- Presentation time
- 8:40 AM ET
- Scheduled time for Harrow’s conference presentation
- Webcast replay duration
- 90 days
- Replay availability period on company website
- Current share price
- $38.605
- Price prior to conference news release
- Price change 24h
- -27.96%
- One-day move ahead of the conference announcement
- Volume today
- 3,933,324 shares
- Trading volume vs 20-day average of 694,680
- 52-week high
- $54.85
- Reference level for current price positioning
- 52-week low
- $20.85
- Reference level for current price positioning
Historical Context
-
FDA cleared IND for Phase 3 TRIESENCE trial in cataract surgery setting.
-
Reported record Q4 and 2025 revenue with 2026 revenue and EBITDA guidance.
-
Announced timing of Q4 and year-end 2025 results and conference call.
-
Launched PharmaPack cash-pay kits as FDA-approved ophthalmic alternatives.
-
OSRX confirmed ongoing licensing and availability of compounded ophthalmic meds.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
ophthalmic medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at Leerink Partner’s 2026 Global Healthcare Conference on Tuesday, March 10, 2026, at 8:40 AM ET, in Miami, Florida.
The presentation will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.
Contact:
Mike Biega, Vice President of Investor Relations and Communications
mbiega@harrowinc.com
617-913-8890
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.